Malignant Peritoneal and Retroperitoneal Neoplasm

Malignant Peritoneal and Retroperitoneal Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

631 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 163
Recruiting: 76
Ph III recruiting: 8
Growth YoY: −39.1%
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (92)

clinicaltrialsPublishedShowing 1–8 of 8 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07776691	A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)	recruiting	Phase 3	802	Merck Sharp & Dohme LLCINDUSTRY	2	Sep 24, 2026	clinicaltrials
NCT07708753	A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers	recruiting	Phase 3	460	CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY	1	Sep 23, 2026